SCTX Scribe Therapeutics Inc.
16.33USD+0.74%Mkt Cap: 309.15M $P/E: —2d ago
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on ca…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap309.15M USD
Enterprise Value429.77M USD
Revenue (TTM)33.30M USD
Gross Profit-17.75M USD
Net Income (TTM)-21.81M USD
Revenue/Share13.58 USD
Last Price16.33 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees82
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.52
PEG—
EV/EBITDA-15.45
EV/Revenue12.91
P/S9.28
P/B-0.25
EPS (TTM)-3.86
EPS (Forward)-3.62
52W Range
13.5011% of range39.60
52W High39.60 USD
52W Low13.50 USD
Profitability
Gross Margin-53.29%
Oper. Margin-489.83%
EBITDA Margin-83.54%
Profit Margin-42.62%
ROE15.21%
ROA-27.88%
Growth
Revenue Growth-60.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.21M USD
CapEx (TTM)1.27M USD
FCF Margin—
FCF Yield—
Net Debt261.00K USD
Net Debt/EBITDA-0.01
Balance Sheet
Debt/Equity-0.29
Current Ratio0.57
Quick Ratio0.56
Book Value/Sh-64.31 USD
Cash/Share2.27 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)57.00 USD
Upside (mean)+249.1%
Target Range50.00 USD – 60.00 USD
50.00+249.1% to mean60.00
# Analysts4
Ownership
Shares Out.18.93M
Float6.89M
Insiders10.70%
Institutions53.80%
Short Interest
Short Ratio3.3d
Short % Out.4.18%
Shares Short790.54K
Short (prev mo.)284.71K
Technical
SMA 5025.87 (-36.9%)
SMA 20025.87 (-36.9%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)445.49K
Avg Vol (10d)651.06K
Technical Indicators
RSI (14)31.8
MACD-3.0887
MACD Signal-1.7975
MACD Hist.-1.2912
BB Upper36.59 USD
BB Middle24.96 USD
BB Lower13.33 USD
BB Width93.22%
ATR (14)3.426 USD
Vol Ratio (20d)0.84x